Taysha Gene Therapies, Inc. $TSHA Position Lowered by Aberdeen Group plc

Aberdeen Group plc cut its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 87.9% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 281,406 shares of the company’s stock after selling 2,045,746 shares during the period. Aberdeen Group plc owned about 0.09% of Taysha Gene Therapies worth $1,370,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its position in Taysha Gene Therapies by 534.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,975,605 shares of the company’s stock worth $27,074,000 after buying an additional 3,349,244 shares in the last quarter. Pictet Asset Management Holding SA boosted its stake in shares of Taysha Gene Therapies by 19.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 3,313,062 shares of the company’s stock valued at $16,135,000 after buying an additional 542,361 shares during the period. ADAR1 Capital Management LLC boosted its stake in shares of Taysha Gene Therapies by 19.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company’s stock valued at $13,318,000 after buying an additional 483,620 shares during the period. Seven Fleet Capital Management LP grew its holdings in shares of Taysha Gene Therapies by 140.4% during the 2nd quarter. Seven Fleet Capital Management LP now owns 1,504,400 shares of the company’s stock valued at $9,940,000 after acquiring an additional 878,692 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its holdings in shares of Taysha Gene Therapies by 53.0% during the 1st quarter. Rice Hall James & Associates LLC now owns 1,944,671 shares of the company’s stock valued at $8,693,000 after acquiring an additional 674,026 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $3.72 on Friday. The firm has a market cap of $1.21 billion, a PE ratio of -8.65 and a beta of 1.36. The firm’s 50 day moving average price is $4.35 and its 200 day moving average price is $5.26. The company has a debt-to-equity ratio of 0.13, a quick ratio of 18.56 and a current ratio of 18.56. Taysha Gene Therapies, Inc. has a twelve month low of $3.45 and a twelve month high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03. As a group, research analysts expect that Taysha Gene Therapies, Inc. will post -0.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TSHA has been the topic of a number of research reports. Wolfe Research assumed coverage on shares of Taysha Gene Therapies in a research note on Thursday, September 17th. They issued an “outperform” rating on the stock. Wall Street Zen raised Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus target price of $12.75.

Check Out Our Latest Research Report on Taysha Gene Therapies

About Taysha Gene Therapies

(Free Report)

Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company’s lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha’s research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.

Further Reading

Want to see what other hedge funds are holding TSHA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report).

Institutional Ownership by Quarter for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.